Epstein-Barr virus mir-bart1-5p detection via nasopharyngeal brush sampling is effective for diagnosing nasopharyngeal carcinoma

Oncotarget

Volumn 7, Issue 4, 2016, Pages 4972-4980

  Zheng, Xiao Hui ^a   Lu, Li Xia ^a   Cui, Cui ^a   Chen, Ming Yuan ^a   Li, Xi Zhao ^a   Jia, Wei Hua ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Biomarker; Epstein barr virus; MicroRNA; Nasopharyngeal brush; Nasopharyngeal carcinoma

Indexed keywords

MICRORNA; MICRORNA BART1 5P; MICRORNA BART17 5P; MICRORNA BART5; MICRORNA BART6 5P; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MIRN-BART1 MICRORNA, HUMAN; VIRUS DNA;

ADULT; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EPSTEIN BARR VIRUS; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NASOPHARYNGEAL SWAB; NASOPHARYNX CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; SMEAR; TUMOR BIOPSY; CASE CONTROL STUDY; COMPARATIVE STUDY; EPSTEIN-BARR VIRUS INFECTIONS; FOLLOW UP; GENETICS; HEAD AND NECK NEOPLASMS; IN SITU HYBRIDIZATION; ISOLATION AND PURIFICATION; LYMPHOMA; NASOPHARYNGEAL NEOPLASMS; NASOPHARYNGITIS; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; VIROLOGY;

BIOMARKERS; CASE-CONTROL STUDIES; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HERPESVIRUS 4, HUMAN; HUMANS; IN SITU HYBRIDIZATION; LYMPHOMA; MALE; MICRORNAS; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NASOPHARYNGITIS; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84958012828     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6649     Document Type: Article

References (24)

1. Razak AR, Siu LL, Liu FF, Ito E, O'Sullivan B, Chan K. Nasopharyngeal carcinoma: the next challenges. Eur J Cancer. 2010; 46: 1967-1978.
2. He ML, Luo MX, Lin MC, Kung HF. MicroRNAs: Potential diagnostic markers and therapeutic targets for EBV-associated nasopharyngeal carcinoma. Biochim Biophys Acta. 2012; 1825: 1-10.
3. Niedobitek G, Young LS. Epstein-Barr virus persistence and virus-associated tumours. Lancet. 1994; 343: 333-335.
4. Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med. 1995; 333: 693-698.
5. Chan KC, Lo YM. Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. Semin Cancer Biol. 2002; 12: 489-496.
6. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, Jiang RS. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004; 350: 2461-2470.
7. Le QT, Jones CD, Yau TK, Shirazi HA, Wong PH, Thomas EN, Patterson BK, Lee AW, Zehnder JL. A comparison study of different PCR assays in measuring circulating plasma epstein-barr virus DNA levels in patients with nasopharyngeal carcinoma. Clin Cancer Res. 2005; 11: 5700-5707.
8. Yip TT, Ngan RK, Fong AH. Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma. Oral Oncol. 2014; 50: 527-538.
9. Sheen TS, Ko JY, Chang YL, Chang YS, Huang YT, Chang Y, Tsai CH, Hsu MM. Nasopharyngeal swab and PCR for the screening of nasopharyngeal carcinoma in the endemic area: a good supplement to the serologic screening. Head Neck. 1998; 20: 732-738.
10. Tune CE, Liavaag PG, Freeman JL, van den Brekel MW, Shpitzer T, Kerrebijn JD, Payne D, Irish JC, Ng R, Cheung RK, Dosch HM. Nasopharyngeal brush biopsies and detection of nasopharyngeal cancer in a high-risk population. J Natl Cancer Inst. 1999; 91: 796-800.
11. Lin SY, Tsang NM, Kao SC, Hsieh YL, Chen YP, Tsai CS, Kuo TT, Hao SP, Chen IH, Hong JH. Presence of Epstein-Barr virus latent membrane protein 1 gene in the nasopharyngeal swabs from patients with nasopharyngeal carcinoma. Head Neck. 2001; 23: 194-200.
12. Tong JH, Tsang RK, Lo KW, Woo JK, Kwong J, Chan MW, Chang AR, van Hasselt CA, Huang DP, To KF. Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma. Clin Cancer Res. 2002; 8: 2612-2619.
13. Hao SP, Tsang NM, Chang KP. Screening nasopharyngeal carcinoma by detection of the latent membrane protein 1 (LMP-1) gene with nasopharyngeal swabs. Cancer. 2003; 97: 1909-1913.
14. Stevens SJ, Verkuijlen SA, Hariwiyanto B, Harijadi, Paramita DK, Fachiroh J, Adham M, Tan IB, Haryana SM, Middeldorp JM. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA. Int J Cancer. 2006; 119: 608-614.
15. Adham M, Greijer AE, Verkuijlen SA, Juwana H, Fleig S, Rachmadi L, Malik O, Kurniawan AN, Roezin A, Gondhowiardjo S, Atmakusumah D, et al. Epstein-Barr virus DNA load in nasopharyngeal brushings and whole blood in nasopharyngeal carcinoma patients before and after treatment. Clin Cancer Res. 2013; 19: 2175-2186.
16. Zheng XH, Lu LX, Li XZ, Jia WH. Quantification of EBV DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern china. Cancer Sci. 2015; 106: 1196-1201
17. Liavaag PG, Cheung RK, Kerrebijn JD, Freeman JL, Irish JC, Dosch HM. The physiologic reservoir of Epstein-Barr virus does not map to upper aerodigestive tissues. Laryngoscope. 1998; 108: 42-46.
18. Lo AK, Dawson CW, Jin DY, Lo KW. The pathological roles of BART miRNAs in nasopharyngeal carcinoma. J Pathol. 2012; 227: 392-403.
19. Cosmopoulos K, Pegtel M, Hawkins J, Moffett H, Novina C, Middeldorp J, Thorley-Lawson DA. Comprehensive profiling of Epstein-Barr virus microRNAs in nasopharyngeal carcinoma. J Virol. 2009; 83: 2357-2367.
20. Wong AM, Kong KL, Tsang JW, Kwong DL, Guan XY. Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. Cancer. 2012; 118: 698-710.
21. Howe JG, Steitz JA. Localization of Epstein-Barr virusencoded small RNAs by in situ hybridization. Proc Natl Acad Sci U S A. 1986; 83: 9006-9010.
22. Ji MF, Huang QH, Yu X, Liu Z, Li X, Zhang LF, Wang P, Xie SH, Rao HL, Fang F, Guo X, Liu Q, Hong MH, et al. Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China. Cancer. 2014; 120: 1353-1360.
23. Leung SF, Lo YM, Chan AT, To KF, To E, Chan LY, Zee B, Huang DP, Johnson PJ. Disparity of sensitivities in detection of radiation-naive and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein-Barr virus DNA1, 2. Clin Cancer Res. 2003; 9: 3431-3434.
24. Xu FH, Xiong D, Xu YF, Cao SM, Xue WQ, Qin HD, Liu WS, Cao JY, Zhang Y, Feng QS, Chen LZ, Li MZ, Liu ZW, et al. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation. J Natl Cancer Inst. 2012; 104: 1396-1410.